When does the Daratumumab composition of matter patent expire?
The composition of matter patent for daratumumab is expected to expire in 2031 [1].
What happens after the daratumumab patent expires?
Following the expiration of the composition of matter patent, generic versions of daratumumab could become available, potentially leading to lower prices for the medication. This would also open the door for biosimilar competition.
How does daratumumab's patent situation compare to other cancer drugs?
Drug patent expirations are a common event in the pharmaceutical industry, particularly for high-cost cancer therapies like daratumumab. The timeline for patent expiration and subsequent generic or biosimilar entry is a critical factor for market dynamics and patient access [2]. For example, patents for many other blockbuster oncology drugs have also faced challenges or are nearing expiration, paving the way for alternative treatments [3].
Can biosimilars be approved before the patent expires?
Generally, biosimilar manufacturers must wait until key patents, such as the composition of matter patent, have expired before seeking FDA approval and market entry. However, complex patent landscapes and litigation can sometimes influence the exact timing of biosimilar availability [4].
What are the key patents protecting daratumumab?
While the composition of matter patent is a primary protection, daratumumab is also protected by other patents, including those covering methods of use and manufacturing processes. These additional patents can extend market exclusivity beyond the initial composition of matter patent expiration [1][5].
Who is developing generic or biosimilar versions of daratumumab?
Companies specializing in generic and biosimilar drug development are likely to pursue the creation of daratumumab equivalents once patent protections weaken. Specific development pipelines are often proprietary, but publicly available information and patent filings can indicate potential competitors [2][3]. DrugPatentWatch.com provides detailed information on patent filings and expiration timelines for many drugs, including daratumumab [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/
[4] https://drugpatentwatch.com/
[5] https://drugpatentwatch.com/